Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06577155
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-27
Brief Title:
Spinal Nalbuphine for Analgesia in Total Hip Arthroplasty
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Effect of Nalbuphine as an Adjuvant to Levobupivacaine in Subarachnoid Anesthesia in Total Hip Arthroplasty A Double-blind Randomized Controlled Study
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
60 patients ASA I-III undergoing total hip arthroplasty were randomly assigned into one of two groups namely group E n30 where levobupivacaine will be administeral intrathecally and group N n30 where levobupivacaine plus nalbuphine will be administeral intrathecally All patients will receive a standardized multimodal analgesic regimen including a PENG block and PCA morphine Morphine consumption during the first 24 hours postoperatively will be measured and additionally the investigators will record Time of morphine first dose administration NRS scores in static and dynamic conditions in 4 hours 6 hours 12 hours 18 hours 24 hours 36 hours and 48 hours postoperatively complications patient satisfaction and duration of hospitalization
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None